
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
CA4P Gets Orphan Drug Status
The FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin and paclitaxel, the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.
Waltham, MassThe FDA has granted Oxigene's combretastatin A4P (CA4P) orphan drug status for treatment of ovarian cancer. In a phase Ib trial, advanced ovarian cancer patients who had failed previous therapy showed a 67% response rate to CA4P plus carboplatin and paclitaxel, the company said in a news release. This combination is currently being evaluated in a phase II trial in women with platinum-resistant ovarian cancer.
Articles in this issue
over 19 years ago
Triple-Negative Cancers More Common in Young Black Ptsover 19 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'over 19 years ago
Study to Examine Outcomes Disparities in Pediatric ALLover 19 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxover 19 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsover 19 years ago
A Novel Brings a Cancer Research Laboratory to Lifeover 19 years ago
NCCN Reveals New Venous Thromboembolism Guidelineover 19 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caover 19 years ago
FDA Approves Dacogen for Treating All MDS Subtypesover 19 years ago
Noninvasive Ablation Relieves Chronic Chest Wall PainNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.